Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - Pharmaceutical News - ASCO and Tempus Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study [Tehran Times (Iran)] - March 23, 2019

Pharmacy News Article

 1/11/19 - ASCO and Tempus Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR) Study [Tehran Times (Iran)]

The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCOs Targeted Agent and Profiling Utilization (TAPUR) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of Food and Drug Administration-approved, targeted anticancer drugs that are used for the treatment of patients who have both advanced cancer and a potentially actionable genomic alteration. Tumor profiling testing by a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified, College of American Pathologists-accredited lab is required for patients to enroll in the study.

Clinicians who order the Tempus xT 596 gene assay will receive a report that has been optimized for TAPUR participation and includes a summary of those genomic alterations targeted by TAPUR study drugs. This designation is available to entities that demonstrate reporting of TAPUR-specific genes in a format that meets criteria established for the TAPUR Study. Based on the genomic findings reported by Tempus xT, the TAPUR Summary will allow clinical sites to quickly identify and screen patients who may be eligible for the study, based on their genomic profiles.

We are pleased to lend support to clinicians across the country and the countless patients who can benefit from access to targeted therapies made available through this unique precision medicine trial, said Gary Palmer, Chief Medical Officer at Tempus. One of the goals of Tempus is to gather as much information as possible regarding efficacy of targeted therapies in specific clinical situations and we are pleased to offer this report to support the goals of the TAPUR study.

The TAPUR Study enrolls patients with advanced cancer who are not responding to standard treatment and who have genomic alterations in their tumors that can be targeted with a TAPUR Study drug, said Richard L. Schilsky, MD, FACP, FASCO, ASCO Chief Medical Officer and principal investigator of the TAPUR Study. The optimized Tempus report will help TAPUR clinical sites determine who is eligible in a more expedited manner.

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Mar 26: Nutrigenomics - Nutritional Influences on the Genome
Mar 27: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Mar 28: Alternatives and Complements to Prescription Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement